Mersana slumps as FDA puts ovarian cancer studies on hold

Mersana Therapeutics

15/06/2023 13:06

** Shares of drug developer Mersana Therapeutics  MRSN.O 
down 54.3% at $4.20 premarket
    ** U.S. FDA issues a partial clinical hold pausing new
patient enrollment in an early-stage and a late-stage trial for
its lead candidate UpRi, to treat a type of ovarian cancer
    ** The agency's decision follows a submission by co of a
recent safety report that showed five fatal bleeding events
    ** A total of 560 patients are dosed with UpRi to date and
co says the causes of bleeding events remain under investigation
    ** MRSN plans to seek alignment with the FDA to lift the
partial clinical hold and resume enrollment in the trials
    ** As of last close, stock up 62.97% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))